Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05191472 · OUTCOME

Proportion of Participants Discontinuing Treatment Due to Toxicity

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies · Source last updated 2025-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
proportion of participants
Interval / dispersion
Not reported
Time frame
Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months

What was measured

The proportion of participants who reported discontinuing treatment due to a treatment-related toxicity will be reported.

Groups in this outcome

Treatment (Pembrolizumab)

Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Pembrolizumab)3

Reported measurements

Source class 1
Values in proportion of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Pembrolizumab)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
The proportion of participants who reported discontinuing treatment due to a treatment-related toxicity will be reported.
groups
  1. description
    Participants received pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Pembrolizumab)
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 30 days after discontinuing study treatment, approximately 1 year and 8 months
title
Proportion of Participants Discontinuing Treatment Due to Toxicity
type
SECONDARY
unit Of Measure
proportion of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice